CA2039643C - Anti-wart composition - Google Patents
Anti-wart composition Download PDFInfo
- Publication number
- CA2039643C CA2039643C CA 2039643 CA2039643A CA2039643C CA 2039643 C CA2039643 C CA 2039643C CA 2039643 CA2039643 CA 2039643 CA 2039643 A CA2039643 A CA 2039643A CA 2039643 C CA2039643 C CA 2039643C
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- composition
- acid
- local anesthetic
- film forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention pertains to a composition for use in the treatment of warts. The composition is used in the treatment of warts caused by human papilloma virus or against molluscum contagiosum. The composition comprises one or more topical keratolytic agents, a local anesthetic, and a topically acceptable carrier for the keratolytic agent and the anesthetic.
Description
ANTI-WART COMPOSITION
The present invention pertains to a topical composition for use in the treatment of warts. The composition com prises at least one keratolytic agent, a local anesthetic, and a topically acceptable carrier.
Keratolytic agents are well known in the art as effec-tive in removing warts and molluscum contagiosum as well as many other lesions which result from hyperkeratotic skin conditions. It is believed the mechanism of keratolytics l0 involve the dissolution of intracellular cement substance, causing epidermal cells which are infected with wart caus ing virus to be mechanically removed. Normally these agents should not be allowed to contact noninfected skin as they are somewhat caustic in nature and have the potential to cause a great deal of localized pain.
Keratolytics appropriate for use in the present inven-tion include, but are not limited to, salicylic acid, lactic acid, and either mono, di, or tri-chloroacetic acid.
The amount of keratolytic agent present will be that which is therapeutically effective against warts caused by human papilloma virus or against molluscum contagiosum. This is generally from about 15% to about 35% and preferably from 16.5% to 32% by weight of the composition.
Although lactic acid is not traditionally considered to be a keratolytic agent, its use in combination with sali-cylic acid or chloroacetic acid softens the skin thereby im pr;;ving the keratolysis seen with either agent alone. When included, the amount of lactic acid present will be from about 1% to about 20% and preferably from 5% to 16.5% by weight of composition.
20~g~~3 By incorporating a local anesthetic in compounds used for traditional wart therapy, the present invention allevi-ates the localized discomfort and irritation often associ-ated with the application of keratolytics to the skin.
Local anesthetics appropriate for use in the present invention include, but axe not limited to, esters of benzoic acid such as benzocaine, procaine, tetracaine, and chlorop-rocaine, and amides such as bupivacaine, dibucaine, lido-caine, mepivacaine, prilocaine, and etidocaine.
The amount of local anesthetic present will be that which is effective in achieving localized anesthesia in the area to which the anti-wart agent is applied. This is gen-erally from about 0. 5% to about 15% and preferably from 1 %
to 10% by weight of composition.
The topically acceptable carrier is a fluid, e.g. liq-uid or gel. Preferably it is one which dries to a relatively clear and colorless film. Film forming fluids are able to provide a protective layer over the skin during therapy while remaining aesthetically pleasant. The amount of car-tier present will be generally from about 20% to about 80%
and preferably from 21% to 78% by weight of composition.
Examples of film forming fluids appropriate for use in the present invention include, but are not limited to, a flexible collodion or a liquid acrylic. Flexible collodion is preferred.
Flexible collodion is widely used in human and veteri-nary topical preparations. USP specifications call for a solution of nitrocellulose dissolved in 75 parts by volume of ethyl ether and 25 parts pPr volume of ethanol. Tho resultant product is a syrupy fluid, generally pale yellow r~
in color, which when applied to the skin and exposed to air forms a tough, and relatively clear film.
Any of a number of adjuvants which are traditionally included in topical pharmaceutical preparations can be in-s corporated into the present invention. These include, but are not limited to, ethanol, hydroxypropylcellulose, and wa-ter.
In another embodiment the present invention comprises a salt, the anion of which is the salicylic acid, lactic acid or chloroacetic acid anion and the cation of which is the protonated form of benzocaine, procaine, tetracaine, chloro-procaine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, or etidocaine.
The salt can be formed either in situ, i.e. by the con-temporaneous application to the skin of an acidic kera-tolytic agent and a basic local anesthetic or prior to ap-plication when these two elements are brought together in a pharmaceutical preparation.
This embodiment further comprises a topically accept-able carrier for the salt. The carrier is a fluid, e.g. a liquid or a gel. The preferred carrier is a film forming fluid such as liquid acrylic or a flexible collodion. Flex-ible collodion again is preferred.
The present invention also includes the method of treating warts which comprises applying to the wart a compo-sition comprising a therapeutically effective amount of at least one topical keratolytic agent such as salicylic acid, lactic acid, or chloroacetic acid and an anesthetically ef-fective amount of a local anesthetic such as be.~.zocaine, procaine, tetracaine, chloroprocaine, bupivacaine, dibu-caine, lidocaine, mepivacaine, prilocaine, or etidocaine.
The present invention pertains to a topical composition for use in the treatment of warts. The composition com prises at least one keratolytic agent, a local anesthetic, and a topically acceptable carrier.
Keratolytic agents are well known in the art as effec-tive in removing warts and molluscum contagiosum as well as many other lesions which result from hyperkeratotic skin conditions. It is believed the mechanism of keratolytics l0 involve the dissolution of intracellular cement substance, causing epidermal cells which are infected with wart caus ing virus to be mechanically removed. Normally these agents should not be allowed to contact noninfected skin as they are somewhat caustic in nature and have the potential to cause a great deal of localized pain.
Keratolytics appropriate for use in the present inven-tion include, but are not limited to, salicylic acid, lactic acid, and either mono, di, or tri-chloroacetic acid.
The amount of keratolytic agent present will be that which is therapeutically effective against warts caused by human papilloma virus or against molluscum contagiosum. This is generally from about 15% to about 35% and preferably from 16.5% to 32% by weight of the composition.
Although lactic acid is not traditionally considered to be a keratolytic agent, its use in combination with sali-cylic acid or chloroacetic acid softens the skin thereby im pr;;ving the keratolysis seen with either agent alone. When included, the amount of lactic acid present will be from about 1% to about 20% and preferably from 5% to 16.5% by weight of composition.
20~g~~3 By incorporating a local anesthetic in compounds used for traditional wart therapy, the present invention allevi-ates the localized discomfort and irritation often associ-ated with the application of keratolytics to the skin.
Local anesthetics appropriate for use in the present invention include, but axe not limited to, esters of benzoic acid such as benzocaine, procaine, tetracaine, and chlorop-rocaine, and amides such as bupivacaine, dibucaine, lido-caine, mepivacaine, prilocaine, and etidocaine.
The amount of local anesthetic present will be that which is effective in achieving localized anesthesia in the area to which the anti-wart agent is applied. This is gen-erally from about 0. 5% to about 15% and preferably from 1 %
to 10% by weight of composition.
The topically acceptable carrier is a fluid, e.g. liq-uid or gel. Preferably it is one which dries to a relatively clear and colorless film. Film forming fluids are able to provide a protective layer over the skin during therapy while remaining aesthetically pleasant. The amount of car-tier present will be generally from about 20% to about 80%
and preferably from 21% to 78% by weight of composition.
Examples of film forming fluids appropriate for use in the present invention include, but are not limited to, a flexible collodion or a liquid acrylic. Flexible collodion is preferred.
Flexible collodion is widely used in human and veteri-nary topical preparations. USP specifications call for a solution of nitrocellulose dissolved in 75 parts by volume of ethyl ether and 25 parts pPr volume of ethanol. Tho resultant product is a syrupy fluid, generally pale yellow r~
in color, which when applied to the skin and exposed to air forms a tough, and relatively clear film.
Any of a number of adjuvants which are traditionally included in topical pharmaceutical preparations can be in-s corporated into the present invention. These include, but are not limited to, ethanol, hydroxypropylcellulose, and wa-ter.
In another embodiment the present invention comprises a salt, the anion of which is the salicylic acid, lactic acid or chloroacetic acid anion and the cation of which is the protonated form of benzocaine, procaine, tetracaine, chloro-procaine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, or etidocaine.
The salt can be formed either in situ, i.e. by the con-temporaneous application to the skin of an acidic kera-tolytic agent and a basic local anesthetic or prior to ap-plication when these two elements are brought together in a pharmaceutical preparation.
This embodiment further comprises a topically accept-able carrier for the salt. The carrier is a fluid, e.g. a liquid or a gel. The preferred carrier is a film forming fluid such as liquid acrylic or a flexible collodion. Flex-ible collodion again is preferred.
The present invention also includes the method of treating warts which comprises applying to the wart a compo-sition comprising a therapeutically effective amount of at least one topical keratolytic agent such as salicylic acid, lactic acid, or chloroacetic acid and an anesthetically ef-fective amount of a local anesthetic such as be.~.zocaine, procaine, tetracaine, chloroprocaine, bupivacaine, dibu-caine, lidocaine, mepivacaine, prilocaine, or etidocaine.
The following examples will serve to further typify the nature of the invention but should not be construed as a limitation on the scope thereof which is defined solely by the amended claims.
Example 1 Ingredient % Total Comp.
Flexible Collodion .................21.800 Salicylic Acid.........................17.000 Benzocaine..................,...........10.000 Hydroxypropyl Cellulose..................1.200 Ethanol (SD alcohol 40B).......q.s. to 100.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film on the skin.
Example 2 Ingredient % Total Comp.
Salicylic Acid. . . . . . . . . . . . . . " " . " " . . " 27 . 000 Flexible Collodion.................. " " " 21,800 Lactic Acid.............".",.,.,.""""5.000 Hydroxypropyl Cellulose............. " ,. " ,1.500 Lidocaine................................,.1.000 Ethanol. (SD alcohol 40B)......,..q.s. to 100.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film.
Example 3 Ingredient ~ Total CamQ.
Flexible Collodion........................24.500 Chloroaceti.c Acid................,........17.000 Lactic Acid................................5.000 Hydroxypropyl Cellulose...................3.000 Lidocaine..................................2.000 Ethanol (SD alcohol 40E).,.......q.s. to 100.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film.
Example 4 Ingredient % Total Comp.
Flexible Collodion..,.................:...66.000 Salicylic Acid...........................16.500 _ 5 _ (,_-_ Lactic Acid...............................16.500 Tetracaine................ .... ..........1.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film.
Example 1 Ingredient % Total Comp.
Flexible Collodion .................21.800 Salicylic Acid.........................17.000 Benzocaine..................,...........10.000 Hydroxypropyl Cellulose..................1.200 Ethanol (SD alcohol 40B).......q.s. to 100.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film on the skin.
Example 2 Ingredient % Total Comp.
Salicylic Acid. . . . . . . . . . . . . . " " . " " . . " 27 . 000 Flexible Collodion.................. " " " 21,800 Lactic Acid.............".",.,.,.""""5.000 Hydroxypropyl Cellulose............. " ,. " ,1.500 Lidocaine................................,.1.000 Ethanol. (SD alcohol 40B)......,..q.s. to 100.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film.
Example 3 Ingredient ~ Total CamQ.
Flexible Collodion........................24.500 Chloroaceti.c Acid................,........17.000 Lactic Acid................................5.000 Hydroxypropyl Cellulose...................3.000 Lidocaine..................................2.000 Ethanol (SD alcohol 40E).,.......q.s. to 100.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film.
Example 4 Ingredient % Total Comp.
Flexible Collodion..,.................:...66.000 Salicylic Acid...........................16.500 _ 5 _ (,_-_ Lactic Acid...............................16.500 Tetracaine................ .... ..........1.000 The foregoing ingredients are combined in a suitable container and thoroughly mixed to form a uniform prepara-tion. A small amount of the preparation is applied directly to the wart loci. The preparation dries to form a film.
Claims (14)
1. A composition for use in the treatment of warts compris-ing:
at least one topical keratolytic agent in an amount ther-apeutically effective against warts caused by human papilloma virus or against molluscum contagiosum, an anesthetically effective amount of a local anesthetic, and a topically acceptable carrier for said keratolytic agent and said anesthetic.
at least one topical keratolytic agent in an amount ther-apeutically effective against warts caused by human papilloma virus or against molluscum contagiosum, an anesthetically effective amount of a local anesthetic, and a topically acceptable carrier for said keratolytic agent and said anesthetic.
2. The composition according to claim 1 wherein said kera-tolytic agent is salicylic acid, lactic acid, or chloroacetic acid.
3. The composition according to claim 1 wherein said local anesthetic is benzocaine, procaine, tetracaine, chloropro-caine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, or etidocaine.
4. The composition according to claim 1 wherein said carrier is a film forming fluid.
5. The composition according to claim 4 wherein said film forming fluid is a flexible collodion.
6. The composition according to claim 4 wherein said film forming fluid is a liquid acrylic.
7. A salt, the anion of which is the salicylic acid, lactic acid or chloroacetic acid anion and the cation of which is the protonated benzocaine, procaine, tetracaine, chloropro-caine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, or etidocaine cation.
8. A composition comprising:
a salt according to claim 7, and a topically acceptable carrier for said salt.
a salt according to claim 7, and a topically acceptable carrier for said salt.
9. The composition according to claim 8 wherein said carrier is a film forming fluid.
10. The composition according to claim 9 wherein said car-rier is a flexible collodion.
11. The composition according to claim 9 wherein said carrier is a liquid acrylic.
12. The use of a composition comprising a therapeutically effective amount of at least one topical keratolytic agent and an anesthetically effective amount of a local anesthetic to treat warts.
13. The use according to claim 12 wherein said keratolytic agent is salicylic acid, lactic acid, or chloroacetic acid.
14. The use according to claim 12 wherein said local anesthetic is benzocaine, procaine, tetracaine, chloroprocaine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, or etidocaine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52037490A | 1990-05-07 | 1990-05-07 | |
| US520,374 | 1990-05-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2039643A1 CA2039643A1 (en) | 1991-11-08 |
| CA2039643C true CA2039643C (en) | 2002-09-10 |
Family
ID=24072326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2039643 Expired - Fee Related CA2039643C (en) | 1990-05-07 | 1991-04-03 | Anti-wart composition |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2039643C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2423328A3 (en) * | 2007-11-02 | 2012-05-30 | Universitätsklinikum Heidelberg | Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2614779B1 (en) * | 2015-12-01 | 2018-05-04 | Universidad De Sevilla | Composition for systematic chemical treatment of plantar wart |
-
1991
- 1991-04-03 CA CA 2039643 patent/CA2039643C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2423328A3 (en) * | 2007-11-02 | 2012-05-30 | Universitätsklinikum Heidelberg | Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2039643A1 (en) | 1991-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1863468B1 (en) | A topical anaesthetic composition | |
| EP0002425B1 (en) | Local anesthetic mixture for topical application, and process for its preparation | |
| DE2418386C2 (en) | Means for treating acne | |
| US20030072814A1 (en) | Topical pharmaceutical composition for the treatment of warts | |
| KR880000091A (en) | Topical Pharmaceutical Compositions Method of Preparation and Use thereof | |
| UA41989C2 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A GEL FOR THE TREATMENT OF SKIN DISEASES AND A METHOD OF TREATMENT OF INFECTED SKIN | |
| NO891379L (en) | ANESTHETIC SKIN MOISTURE PREPARATION AND PROCEDURE FOR PREPARING THEREOF. | |
| US6821523B2 (en) | Topical administration of pharmacologically active bases in the treatment of warts | |
| BR0014205B1 (en) | TREATMENT SYSTEM FOR INJURYING FABRIC | |
| JPS61186312A (en) | antibacterial cream | |
| US4735802A (en) | Topical dermatological composition and method of treatment | |
| KR870005973A (en) | Derivatives of benzoic acid and benzoic acid esters with anti-inflammatory and analgesic activity | |
| CA2101083C (en) | Improved flexible collodion compositions | |
| CA2039643C (en) | Anti-wart composition | |
| US4518583A (en) | Hemorrhoid and anorectal disease treatment method | |
| JP3899267B2 (en) | Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders | |
| EP0002426B1 (en) | Antiperspirant | |
| US3172805A (en) | Anesthetic preparations containing potentiated 4[3-(p-butoxyphenoxy)-propyl morpholine; 3-butyl-1-(2-dimetylamino ethoxy) isoquinoline; 2-dimethylamino-2' 6'-acetoxylidide | |
| JPS60152415A (en) | Remedy for pimple and pharmaceutical preparation for remedying pimple consisting of carrier impregnated therewith | |
| AU2007221941B2 (en) | A topical anaesthetic composition | |
| CA1142090A (en) | Topical anti-inflammatory composition | |
| JPH0338246B2 (en) | ||
| JPS61186318A (en) | External preparation for athlet's foot | |
| MXPA00010447A (en) | Topical anesthetic formulation | |
| JP2003300866A (en) | Dental surface anesthetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |